LEXEO Therapeutics
PublicLEXEO Therapeutics is now publicly traded
The data on this page reflects LEXEO Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Nov 7, 2023
Last Round
Follow-on Offering
Oct 20, 2025
Total Funding Raised
$617.4M
Company Overview
Lexeo Therapeutics (NAS: LXEO) is a biotechnology company specializing in clinical-stage genetic medicines aimed at revolutionizing disease treatment through innovative science and targeted gene therapies for hereditary and acquired diseases with high unmet needs.
Sector
Healthcare
AI Layer
Non-AI
Keywords
LEXEO Therapeutics Comparables
Compare LEXEO Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Novartis | 70% | |
| Myrtelle Inc. | 57% | |
| Minoryx Therapeutics | 55% |
For institutional investors. Book with your work email.
LEXEO Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Follow-on Offering | Oct 20, 2025 | ||||
| Private Placement | May 28, 2025 | ||||
| Private Placement | Mar 13, 2024 | ||||
| IPO | Nov 7, 2023 | ||||
| Series B | Sep 9, 2021 | ||||
Series A | Jan 7, 2021 |
For institutional investors. Book with your work email.
LEXEO Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Baird | Follow-on Offering |
| Lundbeck Foundation | Series B, Series A |
| Longitude Capital | Series B, Private Placement, Series A |
| Surveyor Capital | Private Placement |
| Janus Henderson Group | Series B, Series A, Private Placement |
| ADAR1 Capital Management | Private Placement |
| Balyasny Asset Management L.P. | Follow-on Offering |
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withSep 22, 2026
Lexeo Therapeutics, Inc. partners with Vivet Therapeutics on research focused on cerebellar targeting and sequential dosing strategies to complement its lead gene therapy program, LX2006, on Sep 22nd '26.
- licenses_technologySep 22, 2026
Lexeo Therapeutics, Inc. signs an option agreement with Apertura Gene Therapy, LLC to license a novel intravenous, blood-brain barrier-crossing capsid expected to enable a less invasive CNS administration route after initial systemic administration of LX2006.
For institutional investors. Book with your work email.
LEXEO Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.